Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort

Breast Cancer Research and Treatment

Volumn 151, Issue 2, 2015, Pages 393-403

  Swaroop, Meyha N ^a   Ferguson, Chantal M ^a   Horick, Nora K ^a   Skolny, Melissa N ^a   Miller, Cynthia L ^a   Jammallo, Lauren S ^a   Brunelle, Cheryl L ^a   O’Toole, Jean A ^a   Isakoff, Steven J ^a   Specht, Michelle C ^a   Taghian, Alphonse G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Arm swelling; Breast cancer; Lymphedema; Quality of life; Taxane chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; TAXANE; TAXOID;

ADJUVANT CHEMOTHERAPY; ADULT; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; COMPLICATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LYMPHEDEMA; MASTECTOMY; MIDDLE AGED; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED-RING COMPOUNDS; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LYMPHEDEMA; MASTECTOMY; MIDDLE AGED; TAXOIDS; TIME FACTORS; YOUNG ADULT;

EID: 84937762734     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3408-1     Document Type: Article

References (68)

1. Paskett ED, Naughton MJ, McCoy TP et al (2007) The epidemiology of arm and hand swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev 16:775–782
2. Sakorafas GH, Peros G, Cataliotti L et al (2006) Lymphedema following axillary lymph node dissection for breast cancer. Surg Oncol 15:153–165
3. Hayes SC, Janda M, Cornish B et al (2008) Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol 26:3536–3542
4. Jager G, Doller W, Roth R (2006) Quality-of-life and body image impairments in patients with lymphedema. Lymphology 39:193–200
5. Ridner SH (2009) The psycho-social impact of lymphedema. Lymphat Res Biol 7:109–112
6. Jammallo LS, Miller CL, Horick NK et al (2014) Factors associated with fear of lymphedema after treatment for breast cancer. Oncol Nurs Forum 41:473–483
7. DiSipio T, Rye S, Newman B et al (2013) Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 14:500–515
8. Norman SA, Localio AR, Kallan MJ et al (2010) Risk factors for lymphedema after breast cancer treatment. Cancer Epidemiol Biomarkers Prev 19:2734–2746
9. Yang EJ, Park WB, Seo KS et al (2010) Longitudinal change of treatment-related upper limb dysfunction and its impact on late dysfunction in breast cancer survivors: a prospective cohort study. J Surg Oncol 101:84–91
10. Lucci A, McCall LM, Beitsch PD et al (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25:3657–3663
11. Park JH, Lee WH, Chung HS (2008) Incidence and risk factors of breast cancer lymphoedema. J Clin Nurs 17:1450–1459
12. Tsai RJ, Dennis LK, Lynch CF et al (2009) The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 16:1959–1972
13. Ahmed RL, Schmitz KH, Prizment AE et al (2011) Risk factors for lymphedema in breast cancer survivors, the Iowa Women’s Health Study. Breast Cancer Res Treat 130:981–991
14. Crosby MA, Card A, Liu J et al (2012) Immediate breast reconstruction and lymphedema incidence. Plast Reconstr Surg 129:789e–795e
15. Swenson KK, Nissen MJ, Leach JW et al (2009) Case-control study to evaluate predictors of lymphedema after breast cancer surgery. Oncol Nurs Forum 36:185–193
16. Soran A, D’Angelo G, Begovic M et al (2006) Breast cancer-related lymphedema—what are the significant predictors and how they affect the severity of lymphedema? Breast J 12:536–543
17. Nesvold IL, Dahl AA, Lokkevik E et al (2008) Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncol 47:835–842
18. Ozaslan C, Kuru B (2004) Lymphedema after treatment of breast cancer. Am J Surg 187:69–72
19. Warren LE, Miller CL, Horick N et al (2014) The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study. Int J Radiat Oncol Biol Phys 88:565–571
20. Jammallo LS, Miller CL, Singer M et al (2013) Impact of body mass index and weight fluctuation on lymphedema risk in patients treated for breast cancer. Breast Cancer Res Treat 142:59–67
21. Togawa K, Ma H, Sullivan-Halley J et al (2014) Risk factors for self-reported arm lymphedema among female breast cancer survivors: a prospective cohort study. Breast Cancer Res 16:414-014-0414-x
22. Zhu YQ, Xie YH, Liu FH et al (2014) Systemic analysis on risk factors for breast cancer related lymphedema. Asian Pac J Cancer Prev 15:6535–6541
23. Lee SH, Min YS, Park HY et al (2012) Health-related quality of life in breast cancer patients with lymphedema who survived more than one year after surgery. J Breast Cancer 15:449–453
24. Haddad P, Farzin M, Amouzegar-Hashemi F et al (2010) A multicentre cross-sectional study of arm lymphedema four or more years after breast cancer treatment in Iranian patients. Breast Cancer 17:281–285
25. Shah C, Wilkinson JB, Baschnagel A et al (2012) Factors associated with the development of breast cancer-related lymphedema after whole-breast irradiation. Int J Radiat Oncol Biol Phys 83:1095–1100
26. Shih YC, Xu Y, Cormier JN et al (2009) Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol 27:2007–2014
27. Kim M, Kim SW, Lee SU et al (2013) A model to estimate the risk of breast cancer-related lymphedema: combinations of treatment-related factors of the number of dissected axillary nodes, adjuvant chemotherapy, and radiation therapy. Int J Radiat Oncol Biol Phys 86:498–503
28. Gartner R, Jensen MB, Kronborg L et al (2010) Self-reported arm-lymphedema and functional impairment after breast cancer treatment—a nationwide study of prevalence and associated factors. Breast 19:506–515
29. Monleon S, Murta-Nascimento C, Bascuas I et al (2014) Lymphedema predictor factors after breast cancer surgery: a survival analysis. Lymphat Res Biol. doi:10.1089/lrb.2013.0042
30. Meeske KA, Sullivan-Halley J, Smith AW et al (2009) Risk factors for arm lymphedema following breast cancer diagnosis in Black women and White women. Breast Cancer Res Treat 113:383–391
31. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983
32. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444
33. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313
34. Martin M, Segui MA, Anton A et al (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363:2200–2210
35. Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23:3686–3696
36. Goble S, Bear HD (2003) Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin N Am 83:943–971
37. Ohsumi S, Shimozuma K, Ohashi Y et al (2012) Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: the national surgical adjuvant study of breast cancer 02. Oncology 82:131–138
38. Qin YY, Li H, Guo XJ et al (2011) Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS ONE 6:e26946
39. Bronstad A, Berg A, Reed RK (2004) Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol 287:H963–H968
40. Piccart MJ, Klijn J, Paridaens R et al (1997) Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15:3149–3155
41. Jung SY, Shin KH, Kim M et al (2014) Treatment factors affecting breast cancer-related lymphedema after systemic chemotherapy and radiotherapy in stage II/III breast cancer patients. Breast Cancer Res Treat 148:91–98
42. Kilbreath SL, Lee MJ, Refshauge KM et al (2013) Transient swelling versus lymphoedema in the first year following surgery for breast cancer. Support Care Cancer 21:2207–2215
43. Lee MJ, Beith J, Ward L et al (2014) Lymphedema following taxane-based chemotherapy in women with early breast cancer. Lymphat Res Biol 12:282–288
44. Stanton AW, Northfield JW, Holroyd B et al (1997) Validation of an optoelectronic limb volumeter (Perometer). Lymphology 30:77–97
45. Tierney S, Aslam M, Rennie K et al (1996) Infrared optoelectronic volumetry, the ideal way to measure limb volume. Eur J Vasc Endovasc Surg 12:412–417
46. O’Toole J, Jammallo LS, Skolny MN et al (2013) Lymphedema following treatment for breast cancer: a new approach to an old problem. Crit Rev Oncol Hematol 88:437–446
47. Ancukiewicz M, Russell TA, Otoole J et al (2011) Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 79:1436–1443
48. Armer JM, Stewart BR (2005) A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol 3:208–217
49. Specht MC, Miller CL, Russell TA et al (2013) Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression? Breast Cancer Res Treat 140:485–494
50. Mackey JR, Martin M, Pienkowski T et al (2013) Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol 14:72–80
51. Ferguson T, Wilcken N, Vagg R et al (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 4:CD004421
52. De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53
53. Sparano JA, Wang M, Martino S et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–1671
54. Giordano SH, Lin YL, Kuo YF et al (2012) Decline in the use of anthracyclines for breast cancer. J Clin Oncol 30:2232–2239
55. Semb KA, Aamdal S, Oian P (1998) Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16:3426–3432
56. Behar A, Pujade-Lauraine E, Maurel A et al (1997) The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication. Br J Clin Pharmacol 43:653–658
57. Hugenholtz-Wamsteker W, Robbeson C, Nijs J et al (2014) The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review. Eur J Cancer Care (Engl). doi:10.1111/ecc.12261
58. Park SI, Jeon WH, Jeung HJ et al (2014) Clinical features of docetaxel chemotherapy-related lymphedema. Lymphat Res Biol 12:197–202
59. Vignes S, Lebrun-Vignes B (2007) Sclerodermiform aspect of arm lymphoedema after treatment with docetaxel for breast cancer. J Eur Acad Dermatol Venereol 21:1131–1133
60. Taylor R, Jayasinghe UW, Koelmeyer L et al (2006) Reliability and validity of arm volume measurements for assessment of lymphedema. Phys Ther 86:205–214
61. Deltombe T, Jamart J, Recloux S et al (2007) Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. Lymphology 40:26–34
62. Ancukiewicz M, Miller CL, Skolny MN et al (2012) Comparison of relative versus absolute arm size change as criteria for quantifying breast cancer-related lymphedema: the flaws in current studies and need for universal methodology. Breast Cancer Res Treat 135:145–152
63. Stout Gergich NL, Pfalzer LA, McGarvey C et al (2008) Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer 112:2809–2819
64. Ancukiewicz M, Russell TA, Otoole J et al (2011) Standardized method for quantification of developing lymphedema in patients treated for breast cancer. Int J Radiat Oncol Biol Phys 79:1436–1443
65. Specht MC, Miller CL, Skolny MN et al (2013) Residual lymph node disease after neoadjuvant chemotherapy predicts an increased risk of lymphedema in node-positive breast cancer patients. Ann Surg Oncol 20:2835–2841
66. Soran A, Ozmen T, McGuire KP et al (2014) The importance of detection of subclinical lymphedema for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection; a prospective observational study. Lymphat Res Biol 12:289–294
67. Ostby PL, Armer JM, Dale PS et al (2014) Surveillance recommendations in reducing risk of and optimally managing breast cancer-related lymphedema. J Pers Med 4:424–447
68. Cormier JN, Xing Y, Zaniletti I et al (2009) Minimal limb volume change has a significant impact on breast cancer survivors. Lymphology 42:161–175